GlassScriptPhysician profile
Ashley K Hammer
NPI 1043506603
$1,873.06
in general payments reported to CMS, 2019-2025
26 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $199 · 2021: $194 · 2022: $235 · 2023: $358 · 2024: $445 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.11 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $385.45 | 2021-2025 | |
| Amgen INC. | $284.14 | 2020-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $247.50 | 2019-2025 | |
| Astellas Pharma US INC | $97.46 | 2021-2025 | Veozah |
| Avion Pharmaceuticals | $81.68 | 2020-2021 | |
| Shield Therapeutics INC | $72.82 | 2024 | |
| Sumitomo Pharma America, INC. | $69.33 | 2023-2025 | Myfembree |
| Mylan Pharmaceuticals INC. | $68.44 | 2020-2022 | |
| Exeltis, USA INC. | $58.67 | 2022-2025 | Slynd |
| Vertical Pharmaceuticals, LLC | $55.98 | 2019-2020 | |
| Exact Sciences Corporation | $53.71 | 2023-2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $47.71 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.08 | 2020-2023 | |
| Millicent US INC | $43.27 | 2024-2025 | Femring, Intrarosa |
| Agile Therapeutics, INC. | $37.67 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $29.54 | 2024-2025 | Paragard T 380a |
| Therapeuticsmd, INC. | $29.27 | 2020-2021 | |
| Organon LLC | $27.28 | 2022-2023 | Nexplanon |
| Convatec INC. | $21.55 | 2023 | |
| Pfizer INC. | $21.17 | 2024 | |
| Sage Therapeutics, LLC | $18.40 | 2025 | Zurzuvae |
| Kci USA, INC. | $18.29 | 2020 | |
| Merck Sharp & Dohme LLC | $15.80 | 2024 | Gardasil, Gardasil 9 |
| Daiichi Sankyo INC. | $14.37 | 2019 | |
| Meditrina | $13.56 | 2021 | |
| Evofem Biosciences, INC. | $12.92 | 2023 | Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.